Please sign in to follow a disease.
NKARTA, Inc.
Clinical trials sponsored by NKARTA, Inc., explained in plain language.
Clinical-stage biotech developing natural killer cell therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Donor immune cells take on autoimmune kidney disease in early trial Results expected Apr 2027 (estimated)
-
Immune cell therapy takes on autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…
Phase 1/2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Donor immune cells take on autoimmune kidney disease in early trial
Disease control Recruiting nowThis study tests an experimental therapy called NKX019, which uses specially engineered immune cells from donors to target and calm overactive immune cells in people with lupus nephritis or primary membranous nephropathy. The trial involves 120 adults who have not responded to st…
Phase 1/2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC